+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Chronic Obstructive Pulmonary Disease: Global Drug Forecast and Market Analysis to 2028

  • ID: 5019184
  • Report
  • March 2020
  • Region: Global
  • 154 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Actavis
  • AstraZeneca
  • Chiesi
  • GlaxoSmithKline
  • Novartis
  • Sunovion
  • MORE
Chronic Obstructive Pulmonary Disease: Global Drug Forecast and Market Analysis to 2028

Summary

Chronic obstructive pulmonary disease (COPD) is a common, preventable, incurable, and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation. Long-term exposure to noxious particles or gases such as cigarette smoke and environmental pollution can induce chronic inflammation in the airways, subsequently causing alveolar abnormalities. Pro-inflammatory cytokines, which are secreted from immune cells such as neutrophils, macrophages, and B cells, and CD4+ and CD8+ T lymphocyte infiltration in the lungs, in addition to elastases, can cause destruction and dysfunction within the airways.

This leads to airflow limitation and causes structural abnormalities such as obstructive bronchiolitis and parenchymal destruction (emphysema). In turn, these changes reduce lung elastic recoil and therefore the ability of the airways to remain open during expiration. Symptoms from such changes include dyspnea, wheezing, chronic cough, and sputum over production, which can impact a patient's physical and mental well-being. Although it is currently unknown if the damage to the airways and lungs can be reversed, treatments and lifestyle changes can help slow the progress of the disease.

Key Highlights
  • During the 10-year forecast period, there are 7 pipeline products that are on track to launch, driving a forecast growth in the 7MM from $10.9B in 2018 to $19.3B in 2028, which represents a CAGR of 5.9%.
  • The percentage of drug-treated patients (receiving maintenance treatment only) will rise across the 7MM with an average AGR of 1.19% across all COPD severity grades, reaching over 23 million by 2028.
  • The entry of inhaled corticosteroids/long-acting beta2-agonists/long-acting muscarinic antagonists (ICS/LABA/LAMA) that will include expensive bronchodilators, will continue to take patient share from LABA and LAMA monotherapies, and ICS/LABA dual therapy to simplify treatment management.
  • The entry of anti-eosinophilic biologics from 2024 will boost overall COPD sales despite the small patient population that these therapies will treat. These therapies are only suitable for COPD patients with high levels of eosinophilia, but hold a high price tag.
Key Questions Answered
  • How will the COPD market landscape in the 7MM (US, France, Germany, Italy, Spain, UK, Japan) change from 2018-2028?
  • What are the most promising late-stage pipeline products for COPD?
  • How do the clinical and commercial attributes of late-stage pipeline products compare with one another, and against existing COPD product options?
  • What are the remaining unmet needs in COPD?
  • What drivers and barriers will affect COPD product sales in the 7MM over the forecast period?
Scope
  • Overview of COPD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
  • Topline COPD market revenue from 2018-2028. Annual cost of treatment and major pipeline product sales in this forecast period are included.
  • Key topics covered include current COPD treatment options, unmet needs and opportunities, and the drivers and barriers affecting COPD product sales in the 7MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global COPD market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global COPD market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the COPD market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • I dentify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Actavis
  • AstraZeneca
  • Chiesi
  • GlaxoSmithKline
  • Novartis
  • Sunovion
  • MORE
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 COPD: Executive Summary
2.1 Sales for COPD by Country, 2018-2028
2.2 GSK continues to dominate the COPD market in 2028
2.3 Despite the Variety of Available Therapies, COPD Remains a Market with High Unmet Need
2.4 Treatments that Reverse the Progression of COPD Remain Elusive
2.5 Pipeline COPD Treatment to Target a Niche Population
2.6 What Do Physicians Think?

3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems
4.3 Symptoms

5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources Used
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for COPD (2018 - 2028)
5.5.1 Total Prevalent Cases of COPD
5.5.2 Sex-Specific Total Prevalent Cases of COPD
5.5.3 Age-Specific Total Prevalent Cases of COPD
5.5.4 Diagnosed Prevalent Cases of COPD
5.5.5 Sex-Specific Diagnosed Prevalent Cases of COPD
5.5.6 Age-Specific Diagnosed Prevalent Cases of COPD
5.5.7 Diagnosed Prevalent Cases of COPD by Severity
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of the Analysis
5.6.3 Strengths of the Analysis

6 Disease Management
6.1 Diagnosis and Treatment Overview
6.2 US
6.3 5EU
6.4 Japan

7 Competitive Assessment
7.1 Overview

8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 Disease-Modifying Treatments to Reverse the Progression of COPD
8.3 Identification of Biomarkers that Predict Efficacy
8.4 Observance of GOLD Guidelines Among General Practitioners
8.5 Improved Clinical Trial Design
8.6 Earlier Diagnosis and Recognition of Symptoms

9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
9.2.1 IL-4/IL-5 inhibitors
9.2.2 IL-33 inhibitors
9.2.3 PDE inhibitors
9.2.4 CFTR modulators

10 Current and Future Players

11 Market Outlook

12 Appendix

List of Tables
Table 1: COPD: Key Metrics in the 7MM
Table 2: GOLD Criteria for the Classification of COPD, 2018
Table 3: Symptoms of COPD
Table 4: Modified mMRC Dyspnea Scale
Table 5: Risk Factors and Comorbidities for COPD
Table 6: Treatment Guidelines for COPD
Table 7: Country Profile - US, 2018
Table 8: Region Profile - 5EU, 2018
Table 9: Country Profile - Japan, 2018
Table 10: Leading Treatments for COPD, 2018
Table 11: Comparison of Therapeutic Classes in Development for COPD, 2018-2028
Table 12: AstraZeneca’s COPD Portfolio Assessment, 2019
Table 13: Chiesi’s COPD Portfolio Assessment, 2019
Table 14: GSK’s COPD Portfolio Assessment, 2019
Table 15: Novartis’ COPD Portfolio Assessment, 2019
Table 16: Sunovion’s COPD Portfolio Assessment, 2019
Table 17: Sunovion’s COPD Portfolio Assessment, 2019
Table 18: Theravance’s COPD Portfolio Assessment, 2019
Table 19: COPD Market - Global Drivers and Barriers, 2018-2028
Table 20: Key Events Impacting Sales for COPD in the US, 2018-2028
Table 21: COPD Market - Drivers and Barriers in the US, 2018-2028
Table 22: Key Events Impacting Sales for COPD in the 5EU, 2018-2028
Table 23: COPD Market - Drivers and Barriers in the 5EU, 2018-2028
Table 24: Key Events Impacting Sales for COPD in the Japan, 2018-2028
Table 25: COPD Market - Global Drivers and Barriers in Japan, 2018-2028
Table 26: Historical and projected launch dates for COPD across the 7MM, 2018-2028
Table 27: Historical and projected expiry dates for COPD across the 7MM, 2018-2028
Table 28: High-Prescribing Physicians (non-KOLs) Surveyed, by Country

List of Figures
Figure 1: Global Sales Forecast by Country for COPD in 2018 and 2028
Figure 2: Analysis of the Company Portfolio Gap in COPD for the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that the Publisher Expects to Be Licensed for the Treatment of COPD During the Forecast Period
Figure 4: Normal Lungs and Lungs with COPD
Figure 5: The Pathogenesis of COPD
Figure 6: Refined ABCD Assessment Tool for COPD, 2018
Figure 7: 7MM, Total Prevalence of COPD, Men and Women, Ages ≥35 Years, 2018
Figure 8: 7MM, Diagnosed Prevalence of COPD, Men and Women, Ages ≥35 Years, 2018
Figure 9: 7MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of COPD
Figure 10: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of COPD
Figure 11: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of COPD by Severity
Figure 12: 7MM, Total Prevalent Cases of COPD, Men and Women, Ages ≥35 Years
Figure 13: 7MM, Total Prevalent Cases of COPD, by Sex, Ages ≥35 Years, 2018
Figure 14: 7MM, Total Prevalent Cases of COPD by Age, Men and Women, 2018
Figure 15: 7MM, Diagnosed Prevalent Cases of COPD, Men and Women, Ages ≥35 Years
Figure 16: 7MM, Diagnosed Prevalent Cases of COPD, by Sex, Ages ≥35 Years, 2018
Figure 17: 7MM, Diagnosed Prevalent Cases of COPD by Age, Men and Women, 2018
Figure 18: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using mMRC Scores - GOLD 2011 Criteria), Men and Women, Ages ≥35 Years, 2018
Figure 19: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using CAT Scores - GOLD 2011 Criteria), Men and Women, Ages ≥35 Years, 2018
Figure 20: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using mMRC Scores - GOLD 2016 Criteria), Men and Women, Ages ≥35 Years, 2018
Figure 21: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using CAT Scores - GOLD 2016 Criteria), Men and Women, Ages ≥35 Years, 2018
Figure 22: COPD Treatment Algorithm
Figure 23: Unmet Needs and Opportunities in COPD
Figure 24: Overview of the Development Pipeline in COPD
Figure 25: Key Phase II/III Trials for Promising Pipeline Agents
Figure 26: Competitive Assessment of Late-Stage Pipeline Agents for COPD
Figure 27: Analysis of the Company Portfolio Gap in COPD During the Forecast Period
Figure 28: Global Sales for COPD by Country, 2018 and 2028
Figure 29: Sales for COPD by Drug Class in the US, 2018 and 2028
Figure 30: Sales for COPD by Drug Class in the 5EU, 2018 and 2028
Figure 31: Sales for COPD by Drug Class in Japan, 2018 and 2028
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AstraZeneca
  • GlaxoSmithKline
  • Regeneron/Sanofi
  • Novartis
  • Chiesi
  • Sunovion
  • Boehringer Ingelheim
  • Theravance
  • Genentech/Roche
  • Verona Pharmaceuticals
  • Almirall
  • Takeda
  • Kyowa Hakko Kirin
  • Actavis
Note: Product cover images may vary from those shown
Adroll
adroll